Significant Potential of Late- and Mid-stage Novartis Hematology Portfolio to be Showcased at Upcoming ASH Meeting
Basel, December 2, 2009 – Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) in a form of chronic myeloid leukemia, demonstrate the strength of the company’s hematology portfolio in advancing the care of patients. The new data, at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, highlight ...